Imago raises $80M to further studies of its treatment for blood and bone-marrow disorders
The San Francisco-based company aims to complete at least one Phase III study by 2025, and it is weighing an IPO next year to fund more.
The San Francisco-based company aims to complete at least one Phase III study by 2025, and it is weighing an IPO next year to fund more.
Startup companies that have raised closed funding rounds in the past week also include C2N Diagnostics, Carbon Health, Stellar Health and Modulus Discovery.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The company plans to the use the money to extend its reach into therapeutic area-related intelligence and outcomes-based contracting for payers.
Amgen's venture arm also invested an undisclosed amount in Israeli digital health incubator eHealth Ventures last year.